Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pig kidney transplant trial aims to free patients from dialysis

NCT ID NCT07696962

Not yet recruiting Disease control Sponsor: Xeno Holdings (US), LLC dba ChoironeX Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early-phase trial tests whether a genetically modified pig kidney combined with thymus tissue can work as a transplant in 4 adults with end-stage kidney disease. The goal is to see if the organ can keep them off dialysis safely for at least 6 months. Participants must be on dialysis, eligible for a human kidney transplant, and have a low chance of getting one within a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
genetically modified pig kidney-thymus transplant
What this could lead to
If successful, this could provide a new source of transplantable organs for people with kidney failure, reducing the need for dialysis and human donor kidneys.
What could go wrong
This is a very early, small trial (4 people). The pig organ may be rejected, cause serious infections, or fail to work long-term. Lifelong immune-suppressing drugs are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Study Site 1

    New York, New York, 10032, United States

    Contact

  • Study Site 2

    New York, New York, 10016, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.